Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.80 |
| ▸ | EGFR | P00533 | 13/20 | 0.80 |
| ▸ | RET | P07949 | 2/20 | 0.80 |
| ▸ | KIF5B | P33176 | 2/20 | 0.80 |
| ▸ | FLT1 | P17948 | 13/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.71 |
| ▸ | FLT4 | P35916 | 11/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.70 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.70 |
| ▸ | TEK | Q02763 | 2/20 | 0.65 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.65 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
| ▸ | CIT | O14578 | 1/20 | 0.65 |
| ▸ | GAK | O14976 | 1/20 | 0.65 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964748 | 0.91 | KDR (0.82) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL1468281 | 0.91 | KDR (0.82) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL7864780 | 0.90 | KDR (0.83) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL17520358 | 0.90 | KDR (0.73) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL5864525 | 0.89 | KDR (1.00) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL17520325 | 0.89 | KDR (0.77) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL1467590 | 0.89 | KDR (0.78) | KDREGFRRETKIF5BFLT1 | |
| Hydrochloric Acid SCHEMBL7866007 | 0.89 | KDR (0.82) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL17520354 | 0.89 | KDR (0.71) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL18979086 | 0.89 | KDR (0.74) | KDREGFRRETKIF5BFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2017197036-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| EP-2613153-A2 | Process for the identification of novel enzyme interacting compounds | Cellzome GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| EP-2613154-A2 | Process for the identification of novel enzyme interacting compounds | Cellzome GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| EP-1891446-B1 | PROCESS FOR THE IDENTIFICATION OF NOVEL ENZYME INTERACTING COMPOUNDS | CELLZOME GMBH (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20090238808-A1 | Process for the identification of novel enzyme interacting compounds | CELLZOME GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| EP-1891446-A1 | PROCESS FOR THE IDENTIFICATION OF NOVEL ENZYME INTERACTING COMPOUNDS | CELLZOME AG (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006134056-A1 | PROCESS FOR THE IDENTIFICATION OF NOVEL ENZYME INTERACTING COMPOUNDS | CELLZOME AG (DE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | KDR 1457/4885EGFR 352/4885RET 526/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | KDR 1183/4885EGFR 234/4885RET 1229/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | KDR 1599/4885EGFR 674/4885RET 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.